• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

成神经管细胞瘤、经典型和间充质神经胶质瘤患者来源细胞系和异种移植模型参考集。

A reference collection of patient-derived cell line and xenograft models of proneural, classical and mesenchymal glioblastoma.

机构信息

QIMR Berghofer Medical Research Institute, Brisbane, Australia.

Royal Brisbane and Women's Hospital, Brisbane, Australia.

出版信息

Sci Rep. 2019 Mar 20;9(1):4902. doi: 10.1038/s41598-019-41277-z.

DOI:10.1038/s41598-019-41277-z
PMID:30894629
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6427001/
Abstract

Low-passage, serum-free cell lines cultured from patient tumour tissue are the gold-standard for preclinical studies and cellular investigations of glioblastoma (GBM) biology, yet entrenched, poorly-representative cell line models are still widely used, compromising the significance of much GBM research. We submit that greater adoption of these critical resources will be promoted by the provision of a suitably-sized, meaningfully-described reference collection along with appropriate tools for working with them. Consequently, we present a curated panel of 12 readily-usable, genetically-diverse, tumourigenic, patient-derived, low-passage, serum-free cell lines representing the spectrum of molecular subtypes of IDH-wildtype GBM along with their detailed phenotypic characterisation plus a bespoke set of lentiviral plasmids for bioluminescent/fluorescent labelling, gene expression and CRISPR/Cas9-mediated gene inactivation. The cell lines and all accompanying data are readily-accessible via a single website, Q-Cell (qimrberghofer.edu.au/q-cell/) and all plasmids are available from Addgene. These resources should prove valuable to investigators seeking readily-usable, well-characterised, clinically-relevant, gold-standard models of GBM.

摘要

从患者肿瘤组织中培养的低传代、无血清细胞系是神经胶质瘤 (GBM) 生物学临床前研究和细胞研究的金标准,但仍广泛使用根深蒂固、代表性差的细胞系模型,这影响了许多 GBM 研究的意义。我们认为,提供适当大小、有意义描述的参考集以及使用这些资源的适当工具,将促进对这些关键资源的更大采用。因此,我们提出了一个经过精心挑选的 12 种易于使用、遗传多样化、致瘤性、患者来源、低传代、无血清细胞系的面板,代表了 IDH 野生型 GBM 的分子亚型谱,以及它们详细的表型特征,外加一套用于生物发光/荧光标记、基因表达和 CRISPR/Cas9 介导的基因失活的定制慢病毒质粒。细胞系和所有伴随的数据都可以通过一个网站 Q-Cell(qimrberghofer.edu.au/q-cell/)轻松访问,所有质粒都可以从 Addgene 获得。这些资源对于寻求易于使用、特征良好、临床相关的 GBM 金标准模型的研究人员来说应该是有价值的。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a858/6427001/7e6a1fcc1179/41598_2019_41277_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a858/6427001/ea8b9b0cc336/41598_2019_41277_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a858/6427001/bc283cdac6e5/41598_2019_41277_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a858/6427001/f181653cf4a9/41598_2019_41277_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a858/6427001/7fc48c1fd97e/41598_2019_41277_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a858/6427001/7e6a1fcc1179/41598_2019_41277_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a858/6427001/ea8b9b0cc336/41598_2019_41277_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a858/6427001/bc283cdac6e5/41598_2019_41277_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a858/6427001/f181653cf4a9/41598_2019_41277_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a858/6427001/7fc48c1fd97e/41598_2019_41277_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a858/6427001/7e6a1fcc1179/41598_2019_41277_Fig5_HTML.jpg

相似文献

1
A reference collection of patient-derived cell line and xenograft models of proneural, classical and mesenchymal glioblastoma.成神经管细胞瘤、经典型和间充质神经胶质瘤患者来源细胞系和异种移植模型参考集。
Sci Rep. 2019 Mar 20;9(1):4902. doi: 10.1038/s41598-019-41277-z.
2
Generation of Glioblastoma Patient-Derived Intracranial Xenografts for Preclinical Studies.生成用于临床前研究的胶质母细胞瘤患者来源颅内异种移植物。
Int J Mol Sci. 2020 Jul 20;21(14):5113. doi: 10.3390/ijms21145113.
3
Patient-derived glioblastoma cells show significant heterogeneity in treatment responses to the inhibitor-of-apoptosis-protein antagonist birinapant.源自患者的胶质母细胞瘤细胞对凋亡抑制蛋白拮抗剂比瑞那潘的治疗反应显示出显著的异质性。
Br J Cancer. 2016 Jan 19;114(2):188-98. doi: 10.1038/bjc.2015.420. Epub 2015 Dec 10.
4
Nuclear factor one B (NFIB) encodes a subtype-specific tumour suppressor in glioblastoma.核因子1B(NFIB)在胶质母细胞瘤中编码一种亚型特异性肿瘤抑制因子。
Oncotarget. 2016 May 17;7(20):29306-20. doi: 10.18632/oncotarget.8720.
5
Glioblastoma Exhibits Inter-Individual Heterogeneity of TSPO and LAT1 Expression in Neoplastic and Parenchymal Cells.胶质母细胞瘤在肿瘤细胞和实质细胞中表现出 TSPO 和 LAT1 表达的个体间异质性。
Int J Mol Sci. 2020 Jan 17;21(2):612. doi: 10.3390/ijms21020612.
6
High content screening of patient-derived cell lines highlights the potential of non-standard chemotherapeutic agents for the treatment of glioblastoma.对患者来源细胞系进行高通量筛选,突出了非标准化疗药物治疗神经胶质瘤的潜力。
PLoS One. 2018 Mar 2;13(3):e0193694. doi: 10.1371/journal.pone.0193694. eCollection 2018.
7
Dissecting inherent intratumor heterogeneity in patient-derived glioblastoma culture models.剖析患者来源的胶质母细胞瘤培养模型中固有的肿瘤内异质性。
Neuro Oncol. 2017 Jun 1;19(6):820-832. doi: 10.1093/neuonc/now253.
8
A recombinant lentiviral PDGF-driven mouse model of proneural glioblastoma.一个由重组慢病毒 PDGF 驱动的神经前体细胞型胶质母细胞瘤小鼠模型。
Neuro Oncol. 2018 Feb 19;20(3):332-342. doi: 10.1093/neuonc/nox129.
9
Gene signatures of quiescent glioblastoma cells reveal mesenchymal shift and interactions with niche microenvironment.静息性胶质母细胞瘤细胞的基因特征揭示了间充质转化以及与肿瘤微环境的相互作用。
EBioMedicine. 2019 Apr;42:252-269. doi: 10.1016/j.ebiom.2019.03.064. Epub 2019 Apr 3.
10
Glioblastoma Model Using Human Cerebral Organoids.使用人类大脑类器官的胶质母细胞瘤模型。
Cell Rep. 2018 Apr 24;23(4):1220-1229. doi: 10.1016/j.celrep.2018.03.105.

引用本文的文献

1
Inhibiting the RNA helicase DDX3X in Burkitt lymphoma induces oxydative stress and impedes tumor progression in xenografts.抑制伯基特淋巴瘤中的RNA解旋酶DDX3X可诱导氧化应激并阻碍异种移植瘤的肿瘤进展。
Front Cell Dev Biol. 2025 Jul 23;13:1642006. doi: 10.3389/fcell.2025.1642006. eCollection 2025.
2
HIV Vpr activates a nucleolar-specific ATR pathway to degrade the nucleolar stress sensor CCDC137.人类免疫缺陷病毒Vpr激活一种核仁特异性的ATR途径,以降解核仁应激传感器CCDC137。
Nucleic Acids Res. 2025 Jun 6;53(11). doi: 10.1093/nar/gkaf531.
3
Weaponizing CRISPR/Cas9 for selective elimination of cells with an aberrant genome.

本文引用的文献

1
Tumor Evolution of Glioma-Intrinsic Gene Expression Subtypes Associates with Immunological Changes in the Microenvironment.胶质瘤内在基因表达亚型的肿瘤进化与微环境中的免疫变化相关。
Cancer Cell. 2017 Jul 10;32(1):42-56.e6. doi: 10.1016/j.ccell.2017.06.003.
2
Cyclin-dependent kinase 7 is a therapeutic target in high-grade glioma.细胞周期蛋白依赖性激酶7是高级别胶质瘤的一个治疗靶点。
Oncogenesis. 2017 May 15;6(5):e336. doi: 10.1038/oncsis.2017.33.
3
Dianthin-30 or gelonin versus monomethyl auristatin E, each configured with an anti-calcitonin receptor antibody, are differentially potent in vitro in high-grade glioma cell lines derived from glioblastoma.
将CRISPR/Cas9技术用于选择性消除基因组异常的细胞。
DNA Repair (Amst). 2025 May;149:103840. doi: 10.1016/j.dnarep.2025.103840. Epub 2025 Apr 26.
4
Enhanced detection of glioblastoma vasculature with superparamagnetic iron oxide nanoparticles and MRI.利用超顺磁性氧化铁纳米颗粒和磁共振成像增强胶质母细胞瘤脉管系统的检测
Sci Rep. 2025 Apr 24;15(1):14283. doi: 10.1038/s41598-025-97943-y.
5
Unidirectional recruitment between MeCP2 and KSHV-encoded LANA revealed by CRISPR/Cas9 recruitment assay.通过CRISPR/Cas9招募分析揭示的MeCP2与卡波西肉瘤相关疱疹病毒编码的LANA之间的单向招募
PLoS Pathog. 2025 Mar 10;21(3):e1012972. doi: 10.1371/journal.ppat.1012972. eCollection 2025 Mar.
6
PARP inhibitor radiosensitization enhances anti-PD-L1 immunotherapy through stabilizing chemokine mRNA in small cell lung cancer.PARP抑制剂放射增敏作用通过稳定小细胞肺癌中的趋化因子mRNA来增强抗PD-L1免疫疗法。
Nat Commun. 2025 Mar 4;16(1):2166. doi: 10.1038/s41467-025-57257-z.
7
In Vitro Evaluation of Genetically Unmodified Ligand-Armed Allogeneic Natural Killer Cells to Treat EGFR-Positive Glioblastoma.未经基因改造的配体武装同种异体自然杀伤细胞治疗表皮生长因子受体阳性胶质母细胞瘤的体外评估
Cells. 2025 Feb 11;14(4):254. doi: 10.3390/cells14040254.
8
STING-induced noncanonical autophagy regulates endolysosomal homeostasis.STING诱导的非经典自噬调节内溶酶体稳态。
Proc Natl Acad Sci U S A. 2025 Feb 25;122(8):e2415422122. doi: 10.1073/pnas.2415422122. Epub 2025 Feb 21.
9
PSPC1 exerts an oncogenic role in AML by regulating a leukemic transcription program in cooperation with PU.1.PSPC1通过与PU.1协同调节白血病转录程序,在急性髓系白血病中发挥致癌作用。
Cell Stem Cell. 2025 Mar 6;32(3):463-478.e6. doi: 10.1016/j.stem.2025.01.010. Epub 2025 Feb 14.
10
Opportunities and challenges for patient-derived models of brain tumors in functional precision medicine.功能性精准医学中脑肿瘤患者衍生模型的机遇与挑战
NPJ Precis Oncol. 2025 Feb 14;9(1):47. doi: 10.1038/s41698-025-00832-w.
与单甲基澳瑞他汀E一样,配置有抗降钙素受体抗体的地辛-30或凝胶onin在源自胶质母细胞瘤的高级别胶质瘤细胞系中体外效力存在差异。
Cancer Immunol Immunother. 2017 Sep;66(9):1217-1228. doi: 10.1007/s00262-017-2013-z. Epub 2017 May 13.
4
Development and Biological Evaluation of a Photoactivatable Small Molecule Microtubule-Targeting Agent.一种光可激活的小分子微管靶向剂的研发及生物学评价
ACS Med Chem Lett. 2017 Mar 15;8(4):395-400. doi: 10.1021/acsmedchemlett.6b00483. eCollection 2017 Apr 13.
5
Structural Optimization and Pharmacological Evaluation of Inhibitors Targeting Dual-Specificity Tyrosine Phosphorylation-Regulated Kinases (DYRK) and CDC-like kinases (CLK) in Glioblastoma.胶质母细胞瘤中靶向双特异性酪氨酸磷酸化调节激酶(DYRK)和类CDC激酶(CLK)的抑制剂的结构优化与药理学评价
J Med Chem. 2017 Mar 9;60(5):2052-2070. doi: 10.1021/acs.jmedchem.6b01840. Epub 2017 Feb 28.
6
Anti-GD2-ch14.18/CHO coated nanoparticles mediate glioblastoma (GBM)-specific delivery of the aromatase inhibitor, Letrozole, reducing proliferation, migration and chemoresistance in patient-derived GBM tumor cells.抗GD2-ch14.18/CHO包被的纳米颗粒介导芳香化酶抑制剂来曲唑对胶质母细胞瘤(GBM)的特异性递送,降低患者来源的GBM肿瘤细胞的增殖、迁移和化疗耐药性。
Oncotarget. 2017 Mar 7;8(10):16605-16620. doi: 10.18632/oncotarget.15073.
7
COSMIC: somatic cancer genetics at high-resolution.COSMIC:高分辨率体细胞癌遗传学
Nucleic Acids Res. 2017 Jan 4;45(D1):D777-D783. doi: 10.1093/nar/gkw1121. Epub 2016 Nov 28.
8
Nuclear factor one B (NFIB) encodes a subtype-specific tumour suppressor in glioblastoma.核因子1B(NFIB)在胶质母细胞瘤中编码一种亚型特异性肿瘤抑制因子。
Oncotarget. 2016 May 17;7(20):29306-20. doi: 10.18632/oncotarget.8720.
9
Differential response of patient-derived primary glioblastoma cells to environmental stiffness.患者来源的原发性胶质母细胞瘤细胞对环境硬度的差异反应。
Sci Rep. 2016 Mar 21;6:23353. doi: 10.1038/srep23353.
10
Patient-derived glioblastoma cells show significant heterogeneity in treatment responses to the inhibitor-of-apoptosis-protein antagonist birinapant.源自患者的胶质母细胞瘤细胞对凋亡抑制蛋白拮抗剂比瑞那潘的治疗反应显示出显著的异质性。
Br J Cancer. 2016 Jan 19;114(2):188-98. doi: 10.1038/bjc.2015.420. Epub 2015 Dec 10.